Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysis
Avtorji:Čufer, Tanja (Avtor)
Ciuleanu, Tudor (Avtor)
Berzinec, Peter (Avtor)
Galffy, Gabriela (Avtor)
Jakopović, Marko (Avtor)
Jassem, Jacek (Avtor)
Jovanovic, Dragana (Avtor)
MIhaylova, Zhasmina (Avtor)
Ostoros, Gyula (Avtor)
Thallinger, Christiane (Avtor)
Zemanova, Milada (Avtor)
Zielinski, Christoph (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.
Ključne besede:non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe
Leto izida:2020
Založnik:Wiley Periodicals, Inc. on behalf of AlphaMed Press
Izvor:ZDA
UDK:616-006
ISSN pri članku:1549-490X
OceCobissID:521539609 Povezava se odpre v novem oknu
COBISS_ID:2048592241 Povezava se odpre v novem oknu
DOI:10.1634/theoncologist.2019-0523 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Opis vira z dne 6. 12. 2019;
Število ogledov:1108
Število prenosov:590
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (341,24 KB)
URL URL - Izvorni URL, za dostop obiščite https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1634/theoncologist.2019-0523
 
Nadgradivo:Oncologist
AlphaMed Press
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2019 The Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:24.07.2020

Nazaj